Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel Strategy for the Management of Cervical Multicystic Diseases.
Yoshino A, Kobayashi E, Tsuboyama T, Fukui H, Tomiyama N, Sato K, Morii E, Nakatani E, Komura N, Sawada I, Tanaka Y, Hori K, Yoshimura A, Takahashi R, Iwamiya T, Hisa T, Nishimura S, Kitai T, Yokota H, Shindo M, Miyata H, Hashimoto N, Sakiyama K, Abe H, Ueda Y, Kimura T. Yoshino A, et al. Among authors: komura n. Ann Surg Oncol. 2023 May;30(5):2964-2973. doi: 10.1245/s10434-022-13033-7. Epub 2023 Mar 15. Ann Surg Oncol. 2023. PMID: 36920588 Free PMC article.
Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review.
Kozasa K, Mabuchi S, Komura N, Yokoi E, Hiromasa K, Sasano T, Kawano M, Matsumoto Y, Kobayashi E, Kimura T. Kozasa K, et al. Among authors: komura n. Oncotarget. 2017 Jul 25;8(33):55394-55404. doi: 10.18632/oncotarget.19560. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903428 Free PMC article.
The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations.
Sasano T, Mabuchi S, Kozasa K, Kuroda H, Kawano M, Takahashi R, Komura N, Yokoi E, Matsumoto Y, Hashimoto K, Sawada K, Morii E, Kimura T. Sasano T, et al. Among authors: komura n. Clin Cancer Res. 2018 Aug 15;24(16):4018-4029. doi: 10.1158/1078-0432.CCR-17-2472. Epub 2018 May 11. Clin Cancer Res. 2018. PMID: 29752277
Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer.
Yokoi E, Mabuchi S, Shimura K, Komura N, Kozasa K, Kuroda H, Takahashi R, Sasano T, Kawano M, Matsumoto Y, Kodama M, Hashimoto K, Sawada K, Kimura T. Yokoi E, et al. Among authors: komura n. Invest New Drugs. 2019 Oct;37(5):818-827. doi: 10.1007/s10637-018-0686-6. Epub 2018 Oct 30. Invest New Drugs. 2019. PMID: 30374654
Prostaglandin E2 produced by myeloid-derived suppressive cells induces cancer stem cells in uterine cervical cancer.
Kuroda H, Mabuchi S, Yokoi E, Komura N, Kozasa K, Matsumoto Y, Kawano M, Takahashi R, Sasano T, Shimura K, Kodama M, Hashimoto K, Sawada K, Morii E, Kimura T. Kuroda H, et al. Among authors: komura n. Oncotarget. 2018 Nov 20;9(91):36317-36330. doi: 10.18632/oncotarget.26347. eCollection 2018 Nov 20. Oncotarget. 2018. PMID: 30555631 Free PMC article.
A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy.
Mabuchi S, Yokoi E, Shimura K, Komura N, Matsumoto Y, Sawada K, Isobe A, Tsutsui T, Kitada F, Kimura T. Mabuchi S, et al. Among authors: komura n. Int J Gynecol Cancer. 2019 Mar;29(3):474-479. doi: 10.1136/ijgc-2018-000070. Epub 2019 Jan 4. Int J Gynecol Cancer. 2019. PMID: 30833436 Clinical Trial.
158 results